A2A Pharmaceuticals leverages proprietary computational systems to accelerate the development of novel drugs for life-threatening diseases like cancer, bacterial infections and muscular dystrophy. The company uniquely designs novel libraries of target-specific molecules rather than screening through existing databases and helps advance high-quality programs through the clinic.